A. Scherpereel (Lille, France), P. E. Postmus (Amsterdam, The Netherlands)
A randomised trial of active symptom control (ASC) with or without chemotherapy (CT) in the treatment of patients with malignant pleural mesothelioma. First results of the Medical Research Council/British Thoracic Society MS01 trial
M. Muers, L. Darlison, P. Fisher, C. Higgs, E. Lowry, M. O‘Brien, M. Peake, R. Rudd, M. Snee, J. Steele, D. Girling, M. Nankivell, M. Parmar, C. Pugh, R. Stephens (Leeds, Leicester, Sheffield, Bradford on Avon, Cambridge, London, United Kingdom)
|   |
Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma
G. AK, M. Metintas, S. Metintas, R. Ozkan, H. Ozden (Eskisehir, Turkey)
| |
Proliferation controlling intercellular signalling pathways in human pleural malignant mesothelioma
J. Zhong, M. M. Cornelsen Gencay, M. Tamm, L. Bubendorf, J. L. Black, M. Roth (Camperdown, New South Wales, Sydney, New South Wales, Australia; Basel, Switzerland)
|  |
Timp-2 expression in the cytologic evaluation of adenocarcinoma pleural effusions
E. Giarnieri, S. Mariotta, G. De Francesco, A. Ricci, D. Silvestri, M. R. Giovagnoli (Rome, Italy)
| |
Is pleural VEGF a useful parameter?
R. Gomez, E. Perez Rodriguez, F. Troncoso, A. Hernando, S. Sanchez, M. Valle, I. Fernandez Navamuel (Madrid, Spain)
| |
Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma
S. Krueger, S. Pauls, F. Mottaghy, A. Buck, H. Schelzig, V. Hombach, S. Reske (Ulm, Germany)
| |
Prognostic factors in diffuse malignant pleural mesothelioma
G. Ak, M. Metintas, S. Metintas, H. Yildirim, S. Erginel, F. Alatas (Eskisehir, Turkey)
| |
Role of blind percutaneous biopsy in suspected malignant pleural effusion
A. Gulati, N. Mani, D. A. Promnitz (Ipswich, United Kingdom)
| |